Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer

Abstract Background The effect of second‐line treatment on overall survival (OS) may be affected by subsequent treatment in patients with non‐small cell lung cancer (NSCLC); however, in such patients, the correlation between post‐progression survival (PPS) and OS is unclear. Our study assessed the c...

Full description

Bibliographic Details
Main Authors: Hisao Imai, Ou Yamaguchi, Keita Mori, Kosuke Hashimoto, Tomoe Akagami, Shun Shinomiya, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
nivolumab
non‐small cell lung cancer
survival
Online Access:https://doi.org/10.1111/1759-7714.13886

Internet

https://doi.org/10.1111/1759-7714.13886

Similar Items